Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Anixa Biosciences Inc. has secured its first Australian patent for its breast cancer vaccine technology, extending exclusivity in Australia until 2040. The patent covers vaccine adjuvants and formulations licensed from Cleveland Clinic. Phase 1 data indicated the vaccine was safe, well-tolerated, and elicited immune re
Anixa Biosciences received an Australian composition-of-matter patent covering its breast cancer vaccine through 2040, complementing IP in the U.S., Europe, China and Japan. The company says a Phase 1 trial met primary endpoints and showed immune responses in over 74% of participants.